Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Accera, a biotechnology company delivering therapies in central nervous system diseases, has closed a series C financing round of $35 million, led by Inventages Venture Capital.
Subscribe to our email newsletter
Inventages was joined in this round by San Diego-based Posco BioVentures and other previous private investors. Inventages and Posco participated in the company’s series A and B rounds.
Proceeds of this financing will be used to begin sales and marketing of the company’s lead product, Axona, which is scheduled to launch in the US in the first quarter of 2009.
Steve Orndorff, founder and CEO of Accera, said: “Closing this transaction in the current difficult financial environment is a testament to the confidence of our investors in the Accera organization and the potential of Axona.”